A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis.

Trial Profile

A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2010

At a glance

  • Drugs Infliximab; Methotrexate
  • Indications Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Centocor
  • Most Recent Events

    • 01 Apr 2010 Results from long-term extension study available in the Annals of the Rheumatic Diseases.
    • 19 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top